Pulmonary pharmacology and therapeutics

Pulmonary pharmacology and therapeutics

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
Jennifer L. Taylor-Cousar, Marcus A. Mall, Bonnie W. Ramsey, Edward F. McKone, Elizabeth Tullis, Gautham Marigowda, Charlotte M. McKee, David Waltz, Samuel M. Moskowitz, Jessica Savage, Fengjuan Xuan, Steven M. Rowe

ERJ Open Research Apr 2019, 5 (2) 00082-2019; DOI: 10.1183/23120541.00082-2019
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus
Shelby Daniel-Wayman, Shamira Shallom, Nabila Azeem, Kenneth N. Olivier, Adrian M. Zelazny, D. Rebecca Prevots

ERJ Open Research Apr 2019, 5 (2) 00154-2018; DOI: 10.1183/23120541.00154-2018
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Christopher J. Ryerson, Martin Kolb, Luca Richeldi, Joyce Lee, Daniel Wachtlin, Susanne Stowasser, Venerino Poletti

ERJ Open Research Apr 2019, 5 (2) 00127-2018; DOI: 10.1183/23120541.00127-2018
Nebulised lipid–polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells
Sebastian Vencken, Camilla Foged, Joanne M. Ramsey, Louise Sweeney, Sally-Ann Cryan, Ronan J. MacLoughlin, Catherine M. Greene

ERJ Open Research Apr 2019, 5 (2) 00161-2018; DOI: 10.1183/23120541.00161-2018
Treatment response in COPD: does FEV₁ say it all? A post hoc analysis of the CRYSTAL study
Konstantinos Kostikas, Timm Greulich, Alexander J. Mackay, Nadine S. Lossi, Maryam Aalamian-Mattheis, Xavier Nunez, Veronica A. Pagano, Francesco Patalano, Andreas Clemens, Claus F. Vogelmeier

ERJ Open Research Feb 2019, 5 (1) 00243-2018; DOI: 10.1183/23120541.00243-2018
Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
Lowie E.G.W. Vanfleteren, Anders Ullman, Anita Nordenson, Anders Andersson, Kristina Andelid, Leonardo M. Fabbri

ERJ Open Research Feb 2019, 5 (1) 00185-2018; DOI: 10.1183/23120541.00185-2018
Valved holding chamber drug delivery is dependent on breathing pattern and device design
Péter Csonka, Lauri Lehtimäki

ERJ Open Research Feb 2019, 5 (1) 00158-2018; DOI: 10.1183/23120541.00158-2018
Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial
James D. Chalmers, Remco S. Djamin, Marjolijn Schouten, Holly R. Keir, Brandon Tan, Joachim G.J.V. Aerts, Jeffrey T-J. Huang, Menno van der Eerden

ERJ Open Research Oct 2018, 4 (4) 00136-2018; DOI: 10.1183/23120541.00136-2018
Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD
Katherine J. Baines, Thomas K. Wright, Peter G. Gibson, Heather Powell, Philip M. Hansbro, Jodie L. Simpson

ERJ Open Research Oct 2018, 4 (4) 00031-2018; DOI: 10.1183/23120541.00031-2018
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C. Magnus Sköld, Sara Tomassetti, Philip Hormel, John L. Stauffer, Indiana Strombom, Klaus-Uwe Kirchgaessler, Toby M. Maher

ERJ Open Research Oct 2018, 4 (4) 00084-2018; DOI: 10.1183/23120541.00084-2018

Main menu

User menu

Search

Pulmonary pharmacology and therapeutics

Pages